Literature DB >> 30541636

Longitudinal Evaluation of Pulmonary Arterial Hypertension in a Rhesus Macaque (Macaca mulatta) Model of HIV Infection.

Rebecca A Tarantelli1, Finja Schweitzer1, Marc A Simon2, Rebecca R Vanderpool2, Ian Christman2, Emily Rayens1, Heather M Kling3, ToniAnn Zullo3, Jonathan P Carney4, Brian J Lopresti4, Thomas Bertero5, Stephen Y Chan2, Karen A Norris6.   

Abstract

Pulmonary arterial hypertension (PAH) is a life-threatening disease with higher incidence in HIV-infected compared with noninfected patients. SIV-infected NHP develop clinical manifestations of HIV infection, including PAH. To understand the pathogenesis of PAH and determine the relationship between hemodynamic changes and clinical characteristics associated with SIV infection, we performed right heart catheterization and echocardiographic imaging of 21 rhesus macaques before and after SIV infection. Between 6 and 12 mo after infection, 11 of the 21 animals had elevated mean pulmonary arterial pressure (mPAP; greater than 25 mm Hg). RV involvement was evident as increased RV glucose uptake in PAH+ macaques on positron emission tomography-coupled CT compared with uninfected animals. RV and pulmonary vascular collagen deposition were elevated in PAH+ animals. At 12 mo after infection, 6 of the 21 macaques (28.6%) exhibited continued increase in mPAP (progressive PAH), whereas 5 animals (23.8%) had reduced pressure (transient PAH). SIV infection of rhesus macaques led to 3 distinct outcomes with regard to hemodynamic function. Hemodynamic alterations correlated with specific inflammatory profiles and increased RV and pulmonary arterial fibrosis but not with viral load, sex, or CD4+ T-cell levels. This model of a natural cause of PAH provides insight into disease pathways that are important for the development of novel therapeutic targets.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30541636      PMCID: PMC6310202          DOI: 10.30802/AALAS-CM-18-000012

Source DB:  PubMed          Journal:  Comp Med        ISSN: 1532-0820            Impact factor:   0.982


  38 in total

Review 1.  HIV infection, inflammation, immunosenescence, and aging.

Authors:  Steven G Deeks
Journal:  Annu Rev Med       Date:  2011       Impact factor: 13.739

2.  Physiologic changes in a nonhuman primate model of HIV-associated pulmonary arterial hypertension.

Authors:  M Patricia George; Hunter C Champion; Marc Simon; Siobhan Guyach; Rebecca Tarantelli; Heather M Kling; Alexandra Brower; Christopher Janssen; Jessica Murphy; Jonathan P Carney; Alison Morris; Mark T Gladwin; Karen A Norris
Journal:  Am J Respir Cell Mol Biol       Date:  2012-12-13       Impact factor: 6.914

Review 3.  The role of inflammation and autoimmunity in the pathophysiology of pulmonary arterial hypertension.

Authors:  Nada Kherbeck; Mathieu C Tamby; Guillaume Bussone; Hanadi Dib; Frederic Perros; Marc Humbert; Luc Mouthon
Journal:  Clin Rev Allergy Immunol       Date:  2013-02       Impact factor: 8.667

Review 4.  HIV-1 Tat protein and endothelium: from protein/cell interaction to AIDS-associated pathologies.

Authors:  Marco Rusnati; Marco Presta
Journal:  Angiogenesis       Date:  2002       Impact factor: 9.596

5.  HIV-1 Nef induces the release of inflammatory factors from human monocyte/macrophages: involvement of Nef endocytotic signals and NF-kappa B activation.

Authors:  Eleonora Olivetta; Zulema Percario; Gianna Fiorucci; Gianfranco Mattia; Ilaria Schiavoni; Caitriona Dennis; Joachim Jäger; Mark Harris; Gianna Romeo; Elisabetta Affabris; Maurizio Federico
Journal:  J Immunol       Date:  2003-02-15       Impact factor: 5.422

6.  Arteriopathy in macaques infected with simian immunodeficiency virus.

Authors:  L V Chalifoux; M A Simon; D R Pauley; J J MacKey; M S Wyand; D J Ringler
Journal:  Lab Invest       Date:  1992-09       Impact factor: 5.662

7.  Endothelial function in human immunodeficiency virus-infected antiretroviral-naive subjects before and after starting potent antiretroviral therapy: The ACTG (AIDS Clinical Trials Group) Study 5152s.

Authors:  Francesca J Torriani; Lauren Komarow; Robert A Parker; Bruno R Cotter; Judith S Currier; Michael P Dubé; Carl J Fichtenbaum; Mariana Gerschenson; Carol K C Mitchell; Robert L Murphy; Kathleen Squires; James H Stein
Journal:  J Am Coll Cardiol       Date:  2008-08-12       Impact factor: 24.094

8.  A new noninvasive method for the estimation of peak dP/dt.

Authors:  J Rhodes; J E Udelson; G R Marx; C H Schmid; M A Konstam; Z M Hijazi; S A Bova; D R Fulton
Journal:  Circulation       Date:  1993-12       Impact factor: 29.690

9.  Vascular stiffness mechanoactivates YAP/TAZ-dependent glutaminolysis to drive pulmonary hypertension.

Authors:  Thomas Bertero; William M Oldham; Katherine A Cottrill; Sabrina Pisano; Rebecca R Vanderpool; Qiujun Yu; Jingsi Zhao; Yiyin Tai; Ying Tang; Ying-Yi Zhang; Sofiya Rehman; Masataka Sugahara; Zhi Qi; John Gorcsan; Sara O Vargas; Rajan Saggar; Rajeev Saggar; W Dean Wallace; David J Ross; Kathleen J Haley; Aaron B Waxman; Victoria N Parikh; Teresa De Marco; Priscilla Y Hsue; Alison Morris; Marc A Simon; Karen A Norris; Cedric Gaggioli; Joseph Loscalzo; Joshua Fessel; Stephen Y Chan
Journal:  J Clin Invest       Date:  2016-08-22       Impact factor: 14.808

10.  Metabolism and bioenergetics in the right ventricle and pulmonary vasculature in pulmonary hypertension.

Authors:  Stephen L Archer; Yong-Hu Fang; John J Ryan; Lin Piao
Journal:  Pulm Circ       Date:  2013-01       Impact factor: 3.017

View more
  7 in total

1.  Exploring New Therapeutic Pathways in Pulmonary Hypertension. Metabolism, Proliferation, and Personalized Medicine.

Authors:  M Patricia George; Mark T Gladwin; Brian B Graham
Journal:  Am J Respir Cell Mol Biol       Date:  2020-09       Impact factor: 6.914

Review 2.  The Latest in Animal Models of Pulmonary Hypertension and Right Ventricular Failure.

Authors:  Olivier Boucherat; Vineet Agrawal; Allan Lawrie; Sebastien Bonnet
Journal:  Circ Res       Date:  2022-04-28       Impact factor: 23.213

3.  Monocyte and Alveolar Macrophage Skewing Is Associated with the Development of Pulmonary Arterial Hypertension in a Primate Model of HIV Infection.

Authors:  Finja Schweitzer; Rebecca Tarantelli; Emily Rayens; Heather M Kling; Joshua T Mattila; Karen A Norris
Journal:  AIDS Res Hum Retroviruses       Date:  2018-10-30       Impact factor: 2.205

Review 4.  NHLBI-CMREF Workshop Report on Pulmonary Vascular Disease Classification: JACC State-of-the-Art Review.

Authors:  William M Oldham; Anna R Hemnes; Micheala A Aldred; John Barnard; Evan L Brittain; Stephen Y Chan; Feixiong Cheng; Michael H Cho; Ankit A Desai; Joe G N Garcia; Mark W Geraci; Susan D Ghiassian; Kathryn T Hall; Evelyn M Horn; Mohit Jain; Rachel S Kelly; Jane A Leopold; Sara Lindstrom; Brian D Modena; William C Nichols; Christopher J Rhodes; Wei Sun; Andrew J Sweatt; Rebecca R Vanderpool; Martin R Wilkins; Beth Wilmot; Roham T Zamanian; Joshua P Fessel; Neil R Aggarwal; Joseph Loscalzo; Lei Xiao
Journal:  J Am Coll Cardiol       Date:  2021-04-27       Impact factor: 27.203

5.  Mice with humanized immune system as novel models to study HIV-associated pulmonary hypertension.

Authors:  Valerie J Rodriguez-Irizarry; Alina C Schneider; Daniel Ahle; Justin M Smith; Edu B Suarez-Martinez; Ethan A Salazar; Brianyell McDaniel Mims; Fahmida Rasha; Hanna Moussa; Naima Moustaïd-Moussa; Kevin Pruitt; Marcelo Fonseca; Mauricio Henriquez; Matthias A Clauss; Matthew B Grisham; Sharilyn Almodovar
Journal:  Front Immunol       Date:  2022-08-05       Impact factor: 8.786

6.  Statin treatment prevents the development of pulmonary arterial hypertension in a nonhuman primate model of HIV-associated PAH.

Authors:  Whitney Rabacal; Finja Schweitzer; Emily Rayens; Rebecca Tarantelli; Patrick Whang; Viviana Cobos Jimenez; Judy A Outwater; Karen A Norris
Journal:  Sci Rep       Date:  2019-12-27       Impact factor: 4.996

Review 7.  Ion channels as convergence points in the pathology of pulmonary arterial hypertension.

Authors:  Thibault R H Jouen-Tachoire; Stephen J Tucker; Paolo Tammaro
Journal:  Biochem Soc Trans       Date:  2021-08-27       Impact factor: 5.407

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.